158 related articles for article (PubMed ID: 31419433)
41. Prostate Cancer Genomic Classifier Relates More Strongly to Gleason Grade Group Than Prostate Imaging Reporting and Data System Score in Multiparametric Prostate Magnetic Resonance Imaging-ultrasound Fusion Targeted Biopsies.
Martin DT; Ghabili K; Levi A; Humphrey PA; Sprenkle PC
Urology; 2019 Mar; 125():64-72. PubMed ID: 30552940
[TBL] [Abstract][Full Text] [Related]
42. Combining Prostate Health Index density, magnetic resonance imaging and prior negative biopsy status to improve the detection of clinically significant prostate cancer.
Druskin SC; Tosoian JJ; Young A; Collica S; Srivastava A; Ghabili K; Macura KJ; Carter HB; Partin AW; Sokoll LJ; Ross AE; Pavlovich CP
BJU Int; 2018 Apr; 121(4):619-626. PubMed ID: 29232037
[TBL] [Abstract][Full Text] [Related]
43. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA
Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169
[TBL] [Abstract][Full Text] [Related]
44. Development and validation of nomogram to improve the specificity of multiparametric MRI for clinically significant prostate cancer.
Shiekh M; Houenstein H; Ramahi YO; Shabir U; Ghadersohi S; Zhu D; Zhu M; Jing Z; Attwood K; Kauffman E; Aboumohamed A; Guru K; Hussein AA
Int J Urol; 2023 Oct; 30(10):876-882. PubMed ID: 37329258
[TBL] [Abstract][Full Text] [Related]
45. Application of Prostate Imaging Reporting and Data System Version 2 (PI-RADS v2): Interobserver Agreement and Positive Predictive Value for Localization of Intermediate- and High-Grade Prostate Cancers on Multiparametric Magnetic Resonance Imaging.
Chen F; Cen S; Palmer S
Acad Radiol; 2017 Sep; 24(9):1101-1106. PubMed ID: 28546032
[TBL] [Abstract][Full Text] [Related]
46. Comparison between target magnetic resonance imaging (MRI) in-gantry and cognitively directed transperineal or transrectal-guided prostate biopsies for Prostate Imaging-Reporting and Data System (PI-RADS) 3-5 MRI lesions.
Yaxley AJ; Yaxley JW; Thangasamy IA; Ballard E; Pokorny MR
BJU Int; 2017 Nov; 120 Suppl 3():43-50. PubMed ID: 28749035
[TBL] [Abstract][Full Text] [Related]
47. Multiparametric magnetic resonance imaging of the prostate underestimates tumour volume of small visible lesions.
Sorce G; Stabile A; Lucianò R; Motterle G; Scuderi S; Barletta F; Pellegrino F; Cucchiara V; Gandaglia G; Fossati N; De Cobelli F; Montorsi F; Jeffrey Karnes R; Guccini I; Briganti A
BJU Int; 2022 Feb; 129(2):201-207. PubMed ID: 34038039
[TBL] [Abstract][Full Text] [Related]
48. Evaluation of Prostate Imaging Reporting and Data System Classification in the Prediction of Tumor Aggressiveness in Targeted Magnetic Resonance Imaging/Ultrasound-Fusion Biopsy.
Borkowetz A; Platzek I; Toma M; Renner T; Herout R; Baunacke M; Laniado M; Baretton GB; Froehner M; Zastrow S; Wirth MP
Urol Int; 2017; 99(2):177-185. PubMed ID: 28531902
[TBL] [Abstract][Full Text] [Related]
49. Complementing the active surveillance criteria with multiparametric magnetic resonance imaging.
Kim TU; Baek SR; Song WH; Nam JK; Lee HJ; Park SW
Investig Clin Urol; 2020 Nov; 61(6):573-581. PubMed ID: 33135402
[TBL] [Abstract][Full Text] [Related]
50. Can combined multiparametric magnetic resonance imaging of the prostate and prostate-specific antigen density improve the detection of clinically significant prostate cancer: A prospective single-center cross-sectional study.
Yadav K; Sureka B; Elhence P; Choudhary GR; Pandey H; Garg PK; Yadav T; Khera PS
J Cancer Res Ther; 2021; 17(2):372-378. PubMed ID: 34121679
[TBL] [Abstract][Full Text] [Related]
51. High prostate cancer gene 3 (PCA3) scores are associated with elevated Prostate Imaging Reporting and Data System (PI-RADS) grade and biopsy Gleason score, at magnetic resonance imaging/ultrasonography fusion software-based targeted prostate biopsy after a previous negative standard biopsy.
De Luca S; Passera R; Cattaneo G; Manfredi M; Mele F; Fiori C; Bollito E; Cirillo S; Porpiglia F
BJU Int; 2016 Nov; 118(5):723-730. PubMed ID: 27112799
[TBL] [Abstract][Full Text] [Related]
52. Long-term follow-up results of multiparametric prostate MRI and the prognostic value of PI-RADS: a single-center retrospective cohort study.
Önder Ö; Ayva M; Yaraşır Y; Gürler V; Yazıcı MS; Akdoğan B; Karaosmanoğlu AD; Karçaaltıncaba M; Özmen MN; Akata D
Diagn Interv Radiol; 2024 May; 30(3):139-151. PubMed ID: 37724756
[TBL] [Abstract][Full Text] [Related]
53. Multiparametric magnetic resonance imaging facilitates reclassification during active surveillance for prostate cancer.
Fujihara A; Iwata T; Shakir A; Tafuri A; Cacciamani GE; Gill K; Ashrafi A; Ukimura O; Desai M; Duddalwar V; Stern MS; Aron M; Palmer SL; Gill IS; Abreu AL
BJU Int; 2021 Jun; 127(6):712-721. PubMed ID: 33043575
[TBL] [Abstract][Full Text] [Related]
54. The impact of the relationship between lesion diameter and total core length on the detection rate of clinically significant prostate cancer for PI-RADS 3 lesions.
Yakut E
World J Urol; 2024 Mar; 42(1):162. PubMed ID: 38488892
[TBL] [Abstract][Full Text] [Related]
55. Annual mpMRI surveillance: PI-RADS upgrading and increasing trend correlated with patients who harbor clinically significant disease.
Greenberg JW; Koller CR; Lightfoot C; Brinkley GJ; Leinwand G; Wang J; Krane LS
Urol Oncol; 2024 May; 42(5):158.e11-158.e16. PubMed ID: 38365461
[TBL] [Abstract][Full Text] [Related]
56. Accuracy of Sampling PI-RADS 4-5 Index Lesions Alone by MRI-guided In-bore Biopsy in Biopsy-naive Patients Undergoing Radical Prostatectomy.
Kilic M; Vural M; Coskun B; Acar Ö; Saglican Y; Akpek S; Esen T
Eur Urol Focus; 2020 Mar; 6(2):249-254. PubMed ID: 31054811
[TBL] [Abstract][Full Text] [Related]
57. Systematic Biopsy of the Prostate can Be Omitted in Men with PI-RADS™ 5 and Prostate Specific Antigen Density Greater than 15.
Tafuri A; Iwata A; Shakir A; Iwata T; Gupta C; Sali A; Sugano D; Mahdi AS; Cacciamani GE; Kaneko M; Cai J; Ukimura O; Duddalwar V; Aron M; Gill IS; Palmer SL; Abreu AL
J Urol; 2021 Aug; 206(2):289-297. PubMed ID: 33818141
[TBL] [Abstract][Full Text] [Related]
58. Diagnostic Yield of Incremental Biopsy Cores and Second Lesion Sampling for In-Gantry MRI-Guided Prostate Biopsy.
Seyfried N; Mahran A; Panda A; Obmann VC; Buzzy CA; Jiang Y; Wright KL; Nakamoto DA; Patel IJ; Conroy B; Ponsky L; Gulani V
AJR Am J Roentgenol; 2021 Oct; 217(4):908-918. PubMed ID: 33336582
[No Abstract] [Full Text] [Related]
59. Risk of prostate cancer for men with prior negative biopsies undergoing magnetic resonance imaging compared with biopsy-naive men: A prospective evaluation of the PLUM cohort.
Patel HD; Koehne EL; Shea SM; Bhanji Y; Gerena M; Gorbonos A; Quek ML; Flanigan RC; Goldberg A; Gupta GN
Cancer; 2022 Jan; 128(1):75-84. PubMed ID: 34427930
[TBL] [Abstract][Full Text] [Related]
60. Minimum Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsy Cores Needed for Prostate Cancer Detection: Multivariable Retrospective, Lesion Based Analyses of Patients Treated with Radical Prostatectomy.
Leyh-Bannurah SR; Kachanov M; Beyersdorff D; Tian Z; Karakiewicz PI; Tilki D; Fisch M; Maurer T; Graefen M; Budäus L
J Urol; 2020 Feb; 203(2):299-303. PubMed ID: 31483694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
